In various cancers, such as ovarian, gastric or non-small cell lung cancer, SEMA3A has been found to be downregulated, and this decreased expression has been associated with worse prognoses, increased malignancy, deeper tumor invasion, enhanced metastasis formation, and altered cell adhesion and migration1,5–8. This evidence concerns the gene SEMA3A and cancer.